|
We are a pharmaceutical company currently engaged in the research and
development of innovative pharmaceutical solutions, including an oral insulin
capsule to be used for the treatment of individuals with diabetes, and the use
of orally ingestible capsules or pills for delivery of other polypeptides.
Oral insulin: We are seeking to revolutionize the treatment of diabetes through
our proprietary flagship product, an orally ingestible insulin capsule
(ORMD-0801). We completed a Phase IIb clinical trial on 180 type 2 diabetic
patients that was conducted in 33 sites in the United States. This double-blind,
randomized, 28-day clinical trial was conducted under an Investigational New
Drug application, or IND, with the U.S. Food and Drug Administration, or FDA.
The clinical trial, designed to assess the safety and efficacy of ORMD-0801,
investigated ORMD-0801 over a longer treatment period and had statistical power
to give us greater insight into the drug's efficacy.
|
|